Promomed records double-digit sales growth in January

Promomed's sales in January 2025 increased by 28% year-on-year. Share of revenue from sales of innovative products reached 70%, which is 26 p.p. higher than a year earlier. Notable contribution to the increase in sales was made by the launch of the innovative drug Velgia®, which accounted for 42% of sales in the Endocrinology segment. Shipments of such products as Enligria®, Ambene® Bio, Salvisar®, Reduxin®, oncological drugs, antibiotics, etc. also increased significantly.